Viatris Inc (VTRS) Q1 2026 Earnings Call Transcript

Why It Matters

The results demonstrate Viatris’ resilience amid operational challenges while positioning its pipeline and strategic initiatives to drive higher‑margin growth and sustained shareholder returns.

Key Takeaways

• Total revenue $3.76B, down ~1%
• Operational revenue grew 1% excluding indoor impact
• Greater China sales rose 9%, beating expectations
• Raised and narrowed 2025 guidance on revenue, EBITDA, EPS
• Acquired Aculus Pharma, adding two CNS assets in Japan

Pulse Analysis

Viatris reported first‑quarter 2026 revenue of $3.76 billion, a modest 1 percent decline year‑over‑year, while operational revenue grew 1 percent when the indoor‑facility disruption is excluded. The European market delivered modest gains, emerging markets expanded 7 percent, and Greater China outperformed with a 9 percent sales increase. Adjusted gross margin held steady at 56 percent, and free cash flow reached $658 million, supporting the company’s aggressive capital‑return program. Indoor‑facility remediation is now substantially complete, and the company lifted its 2025 revenue, adjusted EBITDA and EPS outlook, citing favorable foreign‑exchange tailwinds and ongoing buybacks.

The company’s pipeline momentum is a central growth catalyst. A fast‑acting meloxicam NDA, slated for a 2025 submission via the 505(b)(2) pathway, targets the sizable non‑opioid acute‑pain market, while selatogrel and cenerimod Phase 3 enrollments remain on schedule, promising potential blockbuster therapies for myocardial infarction and lupus nephritis. Additional late‑stage assets, including a low‑dose estrogen patch and CNS candidates from the recent Aculus acquisition, broaden the innovative‑brands portfolio and diversify revenue streams. Regulatory filings are underway in multiple regions, and the fast‑acting meloxicam’s opioid‑sparing profile could capture market share from both traditional NSAIDs and opioid therapies.

Management signaled a strategic shift toward higher‑margin complex generics and innovative brands, underscored by an enterprise‑wide cost‑savings review that aims to unlock multiyear efficiencies. The acquisition of Aculus Pharma adds two CNS assets and strengthens Viatris’ foothold in Japan, a market where exclusivity losses pose a risk. The strategic review targets net cost reductions of several hundred million dollars, with a portion earmarked for reinvestment into R&D and commercial capabilities. With over $920 million already returned to shareholders this year and a full‑year capital‑return target exceeding $1 billion, the firm balances disciplined cash deployment with ambitious growth initiatives as it positions for sustained profitability into 2026.